Literature DB >> 11028582

Influenza virus infection in the second and third trimesters of pregnancy: a clinical and seroepidemiological study.

W L Irving1, D K James, T Stephenson, P Laing, C Jameson, J S Oxford, P Chakraverty, D W Brown, A C Boon, M C Zambon.   

Abstract

OBJECTIVE: To determine whether maternal influenza virus infection in the second and third trimesters of pregnancy results in transplacental transmission of infection, maternal auto-antibody production or an increase in complications of pregnancy.
DESIGN: Case-control cohort study. POPULATION: Study and control cohorts were derived from 3,975 women who were consecutively delivered at two Nottingham teaching hospitals between May 1993 and July 1994. A complete set of three sera was available for 1,659 women.
METHODS: Paired maternal ante- and postnatal sera were screened for a rise in anti-influenza virus antibody titre by single radial haemolysis and haemagglutination inhibition. Routine obstetric data collected during and after pregnancy were retrieved from the Nottingham obstetric database. Cord samples were tested for the presence of IgM anti-influenza antibodies, and postnatal infant sera were tested for the persistence of influenza-virus specific IgG. Paired antenatal and postnatal sera were tested against a standard range of auto-antigens by immunofluorescence. MAIN OUTCOME MEASURES: Classification of women as having definite serological evidence of an influenza virus infection in pregnancy (cases) or as controls.
RESULTS: Intercurrent influenza virus infections were identified in 182/1,659 (11.0%) pregnancies. None of 138 cord sera from maternal influenza cases was positive for influenza A virus specific IgM. IgG anti-influenza antibodies did not persist in any of 12 infant sera taken at age 6-12 months. Six of 172 postnatal maternal sera from cases of influenza were positive for auto-antibodies. In all cases the corresponding antenatal serum was also positive for the same auto-antibody. There were no significant differences in pregnancy outcome measures between cases and controls. Overall, there were significantly more complications of pregnancy in the cases versus the controls, but no single type of complication achieved statistical significance.
CONCLUSIONS: Influenza infection in the second and third trimesters of pregnancy is a relatively common event. We found no evidence for transplacental transmission of influenza virus or auto-antibody production in pregnancies complicated by influenza infections. There was an increase in the complications of pregnancy in our influenza cohort.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11028582     DOI: 10.1111/j.1471-0528.2000.tb11621.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  60 in total

1.  Pharmacokinetics of oseltamivir among pregnant and nonpregnant women.

Authors:  Richard H Beigi; Kelong Han; Raman Venkataramanan; Gary D Hankins; Shannon Clark; Mary F Hebert; Thomas Easterling; Anne Zajicek; Zhaoxia Ren; Donald R Mattison; Steve N Caritis
Journal:  Am J Obstet Gynecol       Date:  2011-03-09       Impact factor: 8.661

2.  Impact of maternal immunization on influenza hospitalizations in infants.

Authors:  Katherine A Poehling; Peter G Szilagyi; Mary A Staat; Beverly M Snively; Daniel C Payne; Carolyn B Bridges; Susan Y Chu; Laney S Light; Mila M Prill; Lyn Finelli; Marie R Griffin; Kathryn M Edwards
Journal:  Am J Obstet Gynecol       Date:  2011-02-23       Impact factor: 8.661

3.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.

Authors:  Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia
Journal:  Clin Infect Dis       Date:  2019-03-05       Impact factor: 9.079

Review 4.  Maternal immunization. Clinical experiences, challenges, and opportunities in vaccine acceptance.

Authors:  Michelle H Moniz; Richard H Beigi
Journal:  Hum Vaccin Immunother       Date:  2014-10-30       Impact factor: 3.452

Review 5.  Influenza immunization during pregnancy: Benefits for mother and infant.

Authors:  Isaac G Sakala; Yoshikazu Honda-Okubo; Johnson Fung; Nikolai Petrovsky
Journal:  Hum Vaccin Immunother       Date:  2016-08-05       Impact factor: 3.452

6.  Peripartum outcomes: non-adjuvanted v. adjuvanted H1N1 vaccination.

Authors:  Joel G Ray; Allison J McGeer; Jennifer M Blake; Gerald Lebovic; Graeme N Smith; Mark H Yudin
Journal:  CMAJ       Date:  2014-02-04       Impact factor: 8.262

7.  Persistence of viral RNA in the brain of offspring to mice infected with influenza A/WSN/33 virus during pregnancy.

Authors:  Fredrik Aronsson; Charlotta Lannebo; Martin Paucar; Johan Brask; Krister Kristensson; Håkan Karlsson
Journal:  J Neurovirol       Date:  2002-08       Impact factor: 2.643

8.  Low clinical burden of 2009 pandemic influenza A (H1N1) infection during pregnancy on the island of La Réunion.

Authors:  Patrick Gérardin; Rachid El Amrani; Béatrice Cyrille; Marc Gabrièle; Philippe Guillermin; Malik Boukerrou; Brahim Boumahni; Hanitra Randrianaivo; Arnaud Winer; Jean-Fabien Rouanet; Michel Bohrer; Marie-Christine Jaffar-Bandjee; Pierre-Yves Robillard; Georges Barau; Alain Michault
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

9.  Maternal influenza infection during pregnancy impacts postnatal brain development in the rhesus monkey.

Authors:  Sarah J Short; Gabriele R Lubach; Alexander I Karasin; Christopher W Olsen; Martin Styner; Rebecca C Knickmeyer; John H Gilmore; Christopher L Coe
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

Review 10.  Emerging and zoonotic infections in women.

Authors:  Regan N Theiler; Sonja A Rasmussen; Tracee A Treadwell; Denise J Jamieson
Journal:  Infect Dis Clin North Am       Date:  2008-12       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.